Tibotec Begins Enrollment in Europe for Phase III Trial of Telaprevir in HCV Patients who Failed Prior Treatment
Cork, Ireland, November 20 (ots/PRNewswire) - - Telaprevir Data Presented at AASLD Tibotec BVBA today announced that it has begun enrolling patients in its phase III study of telaprevir (VX-950), an investigational protease inhibitor (PI), in patients with chronic genotype 1 hepatitis C virus (HCV) for ...